Arno Therapeutics, Inc.
ARNI · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $8 | $0 | $0 | $0 |
| Gross Profit | -$8 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $8,653 | $14,840 | $13,476 | $8,537 |
| G&A Expenses | $4,759 | $6,653 | $3,464 | $2,299 |
| SG&A Expenses | $4,759 | $6,653 | $3,464 | $2,299 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13,412 | $21,493 | $16,941 | $10,836 |
| Operating Income | -$13,412 | -$21,493 | -$16,941 | -$10,836 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,904 | $29,264 | -$22,716 | -$3,552 |
| Pre-Tax Income | -$11,508 | $7,771 | -$39,657 | -$14,388 |
| Tax Expense | $28 | $0 | $0 | $0 |
| Net Income | -$11,536 | $7,771 | -$58,226 | -$20,749 |
| % Margin | – | – | – | – |
| EPS | -0.57 | 0.38 | -7.75 | -4.57 |
| % Growth | -250% | 104.9% | -69.6% | – |
| EPS Diluted | -0.57 | 0.31 | -7.75 | -4.57 |
| Weighted Avg Shares Out | 20,409 | 20,382 | 7,516 | 4,540 |
| Weighted Avg Shares Out Dil | 20,409 | 24,810 | 7,516 | 4,540 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $42 | $18 | $8 |
| Interest Expense | $28 | $0 | $18,569 | $6,361 |
| Depreciation & Amortization | $15 | $55 | $31 | $22 |
| EBITDA | -$13,397 | -$21,439 | -$16,910 | -$14,374 |
| % Margin | – | – | – | – |